Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
Cutan Ocul Toxicol ; : 1-21, 2024 Aug 24.
Article in English | MEDLINE | ID: mdl-39180341

ABSTRACT

Background: Test methods to inform hazard characterization and labeling of pesticides to protect human health are typically conducted using laboratory animals, and for skin irritation/corrosion the rabbit Draize test is currently required by many regulatory agencies. Although the Draize test is generally regarded to provide protective classifications for human health, new approach methodologies (NAMs) have been developed that offer more human relevant models that circumvent the uncertainty associated with species differences that exist between rabbits and humans. Despite wide applicability and use of these test methods across a broad range of chemicals, they have not been widely adopted for testing pesticides and pesticidal formulations. One of the barriers to adoption of these methods in this sector is low concordance with results from the Draize rabbit test, particularly for chemicals within the mild to moderate irritation spectrum.Methods: This review compares and contrasts the extent to which available models used in skin irritation testing mimic the anatomy and physiology of human skin, and how each aligns with the known key events leading to chemically-induced adverse skin irritation and corrosion. Doing so fully characterizes the human relevance of each method.Results: As alternatives to the rabbit Draize test, several protocols using ex vivo, in chemico, and in vitro skin models are available as internationally harmonized test guidelines. These methods rely on a variety of models of human skin, including excised rodent skin, synthetic biochemical models of barrier function, cell culture systems, and reconstructed human tissue models. We find these models exhibit biological and mechanistic relevance aligned with human skin irritation responses. Further, recent retrospective analyses have shown that the reproducibility of the Draize test is less than 50% for mild and moderate responses, with many of the replicate predictions spanning more than one category (e.g., a moderate response reported in one study followed by a non-irritant response reported in another study).Conclusions: Based on this comparative evaluation, we recommend top-down and bottom-up testing strategies that use the most human relevant in vitro test methods for skin irritation and corrosion classification of pesticides and pesticide formulations. To further discriminate among mild and non-irritant formulations, optimization of a cytokine release protocol and subsequent analyses of reference formulation test results is recommended.

2.
Cutan Ocul Toxicol ; 37(4): 380-390, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30035615

ABSTRACT

INTRODUCTION: Irritation reactions are a frequently reported occupational illness. The potential adverse effects of pharmaceutical compounds (PCs) on eye and skin can now be assessed using validated in vitro methods. OBJECTIVES: Our overall aim is to reduce animal testing by replacing the historically utilized in vivo test methods with validated in vitro test methods which accurately determine the ocular and dermal irritation/corrosion potential of PCs to inform worker safety within the pharmaceutical space. Bristol-Myers Squibb (BMS) and the Institute for In Vitro Sciences (IIVS) have therefore conceptualized and internally qualified a tiered in vitro testing strategy to inform occupational hazards regarding eye and skin irritation and corrosivity of PCs. For the small scale pre-qualification phase, we paired historical in vivo and newly generated in vitro data for 15 PCs to determine the predictive capacity of in vitro assays already validated for the eye and skin irritation/corrosion endpoints and accepted for certain regulatory submissions. During the post-qualification phase, a group of 24 PCs were subjected exclusively to the developed tiered testing strategy, which is based on three Organisation for Economic Co-operation and Development (OECD) in vitro methods. MATERIALS AND METHODS: The qualified in vitro testing strategy utilizes the Corrositex® assay for the corrosivity (OECD TG 435), the Bovine Corneal Opacity and Permeability (BCOP) assay for ocular irritation (OECD TG 437), and the EpiDerm™ tissue model-based Skin Irritation Test (SIT) for dermal irritation (OECD TG 439). In the first step, the pH of each PC was determined. For compounds with pH extremes ≥11 or ≤2, the Corrositex® assay was generally conducted first. For compound(s) that were incompatible with or were negative in the Corrositex® assay or had pH values between 2 and 11, the BCOP assay and SIT were performed first. RESULTS: The results of the tiered testing strategy's qualification phase demonstrated that the BCOP assay is sensitive enough to identify a wide range of eye irritation/corrosion potentials and its over-prediction rate was considered acceptable to inform occupational hazards and ensure the proper handling practices of PCs. The SIT correctly predicted the skin irritation potential of 14 out of the 15 PCs included in the qualification phase, only over-predicting one PC. In the post-qualification phase, four PCs out of four tested were predicted corrosive by the Corrositex® assay and thus no further testing was needed or conducted. The rest of the PCs were evaluated in the BCOP assay (both neat and as a 20% dilution), with the higher response being used for hazard classification. Four PCs were determined to be severe eye irritants, 1 a moderate irritant, 8 were mild irritants, and 8 were non-irritants. The same set of PCs was evaluated using the SIT and were classified as non-irritants to skin. These results are consistent with the BMS historical in vivo results showing a very low number of PCs as skin irritants. CONCLUSIONS: This tiered in vitro testing strategy, which replaces the use of animal studies, was found to be reasonably accurate in its predictive capacity when compared to historical in vivo results and represents a conservative and reliable platform that can be utilized for the prediction of ocular and dermal irritation/corrosion potential of PCs and for subsequent GHS classification and worker safety hazard communications.


Subject(s)
Animal Testing Alternatives , Drug Industry , Eye Diseases/chemically induced , Irritants/toxicity , Occupational Diseases/prevention & control , Occupational Health , Skin Diseases/chemically induced , Animals , Cattle , Eye Diseases/pathology , Humans , Hydrogen-Ion Concentration , In Vitro Techniques , Irritants/classification , Pharmaceutical Preparations , Predictive Value of Tests , Skin Diseases/pathology
3.
Med Res Rev ; 37(4): 907-935, 2017 07.
Article in English | MEDLINE | ID: mdl-28029168

ABSTRACT

Vitiligo is the most frequent human pigmentary disorder, characterized by progressive autoimmune destruction of mature epidermal melanocytes. Of the current treatments offering partial and temporary relief, ultraviolet (UV) light is the most effective, coordinating an intricate network of keratinocyte and melanocyte factors that control numerous cellular and molecular signaling pathways. This UV-activated process is a classic example of regenerative medicine, inducing functional melanocyte stem cell populations in the hair follicle to divide, migrate, and differentiate into mature melanocytes that regenerate the epidermis through a complex process involving melanocytes and other cell lineages in the skin. Using an in-depth correlative analysis of multiple experimental and clinical data sets, we generated a modern molecular research platform that can be used as a working model for further research of vitiligo repigmentation. Our analysis emphasizes the active participation of defined molecular pathways that regulate the balance between stemness and differentiation states of melanocytes and keratinocytes: p53 and its downstream effectors controlling melanogenesis; Wnt/ß-catenin with proliferative, migratory, and differentiation roles in different pigmentation systems; integrins, cadherins, tetraspanins, and metalloproteinases, with promigratory effects on melanocytes; TGF-ß and its effector PAX3, which control differentiation. Our long-term goal is to design pharmacological compounds that can specifically activate melanocyte precursors in the hair follicle in order to obtain faster, better, and durable repigmentation.


Subject(s)
Melanocytes/pathology , Regenerative Medicine/methods , Stem Cells/pathology , Vitiligo/therapy , Animals , Humans , Melanocytes/drug effects , Regenerative Medicine/trends , Stem Cells/drug effects , Vitiligo/drug therapy , Vitiligo/pathology
4.
Altern Lab Anim ; 44(6): 523-532, 2016 Dec.
Article in English | MEDLINE | ID: mdl-28094534

ABSTRACT

The personal care industry is focused on developing safe, more efficacious, and increasingly milder products, that are routinely undergoing preclinical and clinical testing before becoming available for consumer use on skin. In vitro systems based on skin reconstructed equivalents are now established for the preclinical assessment of product irritation potential and as alternative testing methods to the classic Draize rabbit skin irritation test. We have used the 3-D EpiDerm™ model system to evaluate tissue viability and primary cytokine interleukin-1α release as a way to evaluate the potential dermal irritation of 224 non-ionic, amphoteric and/or anionic surfactant-containing formulations, or individual raw materials. As part of our testing programme, two representative benchmark materials with known clinical skin irritation potential were qualified through repeated testing, for use as references for the skin irritation evaluation of formulations containing new surfactant ingredients. We have established a correlation between the in vitro screening approach and clinical testing, and are continually expanding our database to enhance this correlation. This testing programme integrates the efforts of global manufacturers of personal care products that focus on the development of increasingly milder formulations to be applied to the skin, without the use of animal testing.


Subject(s)
Animal Use Alternatives , Cosmetics/toxicity , Interleukin-1alpha/analysis , Skin Care , Skin Irritancy Tests , Surface-Active Agents/toxicity , Humans
5.
Front Toxicol ; 5: 1256399, 2023.
Article in English | MEDLINE | ID: mdl-37886123

ABSTRACT

Aging is one of the most dynamic biological processes in the human body and is known to carry significant impacts on individuals' self-esteem. Skin pigmentation is a highly heritable trait made possible by complex, strictly controlled cellular and molecular mechanisms. Genetic, environmental and endocrine factors contribute to the modulation of melanin's amount, type and distribution in the skin layers. One of the hallmarks of extrinsic skin aging induced by environmental stress factors is the alteration of the constitutive pigmentation pattern clinically defined as senile lentigines and/or melasma or other pigmentary dyschromias. The complexity of pollutants and tobacco smoke as environmental stress factors warrants a thorough understanding of the mechanisms by which they impact skin pigmentation through repeated and long-term exposure. Pre-clinical and clinical studies demonstrated that pollutants are known to induce reactive oxygen species (ROS) or inflammatory events that lead directly or indirectly to skin hyperpigmentation. Another mechanistic direction is provided by Aryl hydrocarbon Receptors (AhR) which were shown to mediate processes leading to skin hyperpigmentation in response to pollutants by regulation of melanogenic enzymes and transcription factors involved in melanin biosynthesis pathway. In this context, we will discuss a diverse range of New Approach Methodologies (NAMs) capable to provide mechanistic insights of the cellular and molecular pathways involved in the action of environmental stress factors on skin pigmentation and to support the design of raw ingredients and formulations intended to counter their impact and of any subsequently needed clinical studies.

6.
Altern Lab Anim ; 39(4): 317-37, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21942546

ABSTRACT

Mucosal surfaces, such as the vaginal epithelium, are natural barriers to infection that are constantly exposed to bacteria and viruses, and are therefore potential sites of entry for numerous pathogens. The vaginal epithelium can be damaged mechanically, e.g. by the incorrect use of objects such as tampons, and by chemicals that are irritating or corrosive. Consequently, this can lead to an increase in susceptibility to further damage or infection. Pharmaceutical, cosmetic and personal care products that are specifically formulated for application onto human external mucosae can occasionally induce undesirable local or systemic side-effects. Therefore, the compatibility of applied materials with this mucosal surface represents a key issue to be addressed by manufacturers. The most frequently used method for assessing vaginal mucosal irritation is the in vivo rabbit vaginal irritation test. However, the current emphasis in the field of toxicology is to use alternative in vitro methods that reduce, refine, and replace the use of animals, and which model and predict human, not animal, responses. Such an approach is of particular interest to the personal care and cosmetic industries in their effort to comply with European legislative measures, such as the 7th Amendment to the EU Cosmetics Directive that does not permit the marketing of cosmetic products if they, or their ingredients, have been tested for irritation responses in animals. The focus of this review is to provide an overview of the alternative and in vitro tests that are currently available for vaginal mucosal irritation assessment, and which are already used, or may become useful, to establish the safety of newly-designed products for human use.


Subject(s)
Animal Testing Alternatives , Irritants/toxicity , Toxicity Tests/methods , Vagina/drug effects , Animals , Female , Humans , Mice , Rabbits , Swine , Tissue Engineering
7.
Int J Pediatr Endocrinol ; 2020: 16, 2020.
Article in English | MEDLINE | ID: mdl-32944019

ABSTRACT

BACKGROUND: Antifungals act on fungal sterols structurally similar to human cholesterol. Ketoconazole reversibly suppresses steroidogenesis by inhibiting cytochrome P450 enzymes and interferes with dihydrotestosterone (DHT) activity by binding to the androgen receptor. Hypospadias was reported in infants exposed to nystatin in utero. CASE PRESENTATION: A male infant exposed to antepartum nystatin presented with severe under-undervirilization and transient adrenal corticosteroid abnormalities. He was born in USA at 31 weeks gestation to a mother treated with vaginal Polygynax capsules (nystatin-100,000 international units, neomycin sulphate-35,000 international units and polymyxin B-35,000 international units) for vaginal discharge in the Ivory Coast. She used approximately 60 capsules between the first trimester until delivery. The infant was born with micropenis, chordee, perineo-scrotal hypospadias and bifid scrotum with bilaterally palpable gonads. The karyotype was 46,XY. No Mullerian structures were seen on ultrasound. Serum 17-hydroxyprogesterone (17 OHP) on newborn screening was high (304 ng/ml, normal < 35). Cortisol response to cosyntropin on the 3rd day of life (DOL) was 10 mcg/ml; the subnormal cortisol response may have resulted from prematurity and the predelivery treatment with betamethasone. The elevation of several adrenal corticosteroids was not consistent with any specific enzymatic defect. Hydrocortisone and fludrocortisone were initiated at another hospital for suspected mild glucocorticoid and mineralocorticoid deficiencies. Genetic screening for adrenal and gonadal developmental defects performed when transferred to our care were normal. All medications were gradually discontinued over 5-8 months. Adrenal and testicular responses to cosyntropin and human chorionic gonadotropin (hCG) were normal at 8 months. CONCLUSIONS: We report severe undervirilization in a 46,XY infant born to a mother treated with prolonged and high dose nystatin during pregnancy. This presentation suggests that prolonged antepartum use of high dose nystatin could lead to severe but transient defects in androgen synthesis and/or action possibly by acting as an endocrine disruptor. Further studies are warranted to confirm this finding. Thus, endocrine disruptors should be considered in male newborns with atypical genitalia not explained by common pathologies.

8.
Med Res Rev ; 29(3): 514-46, 2009 May.
Article in English | MEDLINE | ID: mdl-19241402

ABSTRACT

Vitiligo is a progressive depigmenting disorder affecting 0.5-2% of the population worldwide in which destruction of functional melanocytes from epidermis is a composite of multiple processes influencing melanocyte function and survival. A number of studies have recently reported that the treatment with vitamin D compounds or their combination with ultraviolet light or corticosteroids enhances repigmentation in vitiligo; however, the causal relationship at the cellular and molecular levels has not so far been investigated. This review details the main intracellular pathways through which vitamin D ligands alone or in different combinations may contribute to pigment restoration in vitiligo, outlines the most recent achievements in vitiligo treatment using vitamin D analogs, and compares their efficacy with other treatment regimens in vitiligo. Based on the reviewed literature and data, we foresee the need for designing new vitamin D compounds to achieve maximal therapeutic efficacy. Such compounds should have high selectivity for melanocytes, stimulatory effects on melanogenesis, and minimal suppressive effects on melanocyte growth. An approach combining clinical investigations and focused research on the cellular and molecular mechanisms of vitiligo repigmentation will lead to finding better treatments for this disease.


Subject(s)
Skin Pigmentation , Vitamin D/analogs & derivatives , Vitamin D/therapeutic use , Vitiligo/drug therapy , Humans , Ligands , Melanocytes/metabolism , Models, Biological , Phytotherapy , Signal Transduction
9.
J Endocr Soc ; 3(4): 838-846, 2019 Apr 01.
Article in English | MEDLINE | ID: mdl-30963141

ABSTRACT

Cortisol and growth hormone (GH) deficiencies are causes of neonatal hypoglycemia. When they coexist, a pituitary disorder is suspected. We present an infant with hypoglycemia in whom an ACTH receptor defect was associated with transient GH deficiency. A full-term boy with consanguineous parents presented with hypoglycemia (serum glucose 18 mg/dL) at 4 hours of life with undetectable serum cortisol (<1 µg/dL). Examination showed diffuse hyperpigmentation with normal male genitalia. Patient developed hyperbilirubinemia and elevated transaminase levels. GH levels of 6.8 ng/mL and 7.48 ng/mL during episodes of hypoglycemia, peak of 9.2 ng/mL with glucagon stimulation, and undetectable IGF-1 suggested GH deficiency. Thyroid function, prolactin, and gonadotropins were normal. Baseline ACTH was elevated at 4868 pg/mL, whereas serum cortisol remained undetectable with ACTH stimulation. Hydrocortisone replacement resulted in normalization of blood glucose and cholestasis with decline in ACTH level. GH therapy was not initiated, given improvement in cholestasis and euglycemia. An ACTH receptor defect was confirmed with molecular genetic testing that revealed homozygosity for a known mutation of the melanocortin 2 receptor (MC2R) gene. At 12 weeks, a random GH level was 10 ng/mL. IGF-1 was 75 ng/mL and 101 ng/mL at 7 and 9 months, respectively. This report describes glucocorticoid deficiency from an MC2R mutation associated with GH deficiency. With glucocorticoid replacement, GH secretion normalized. Our findings are consistent with a previously stated hypothesis that physiologic glucocorticoid levels may be required for optimal GH secretion [1].

10.
Bone ; 42(4): 819-24, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18242158

ABSTRACT

Sixteen patients with primary hyperparathyroidism presenting as rickets have so far been reported in the English literature. However, no report of an ectopic thymic parathyroid adenoma presenting as rickets has been published. We report a 14-year-old Caucasian American, wheelchair-ridden male who presented with signs and symptoms suggestive of vitamin D deficiency rickets subsequently confirmed by laboratory and radiological findings. Following the intramuscular administration of 125,000 U ergocalciferol (vitamin D2), he developed hypercalcemia with persistently elevated parathyroid hormone (PTH) levels suggestive of primary hyperparathyroidism. Sestamibi scan demonstrated significant uptake in the superior chest, without uptake at the normal parathyroid glands location. Surgical exploration revealed normal parathyroid glands and a thymic mass, which was removed and confirmed by pathology to be a parathyroid adenoma. With subsequent oral ergocalciferol solution and calcium carbonate therapies, the patient's symptoms resolved, blood chemistries normalized, and radiological evidence of rickets significantly improved. To our knowledge, this is the first case of an ectopic thymic parathyroid adenoma in a patient presenting with rickets. Our patient demonstrates that hyperparathyroidism-induced hypercalcemia may be masked by severe vitamin D deficiency. Prolonged treatment with ergocalciferol after removal of the parathyroid adenoma was necessary to normalize iPTH and replenish vitamin D store.


Subject(s)
Parathyroid Neoplasms/pathology , Rickets , Vitamin D Deficiency , Adolescent , Calcium/blood , Calcium/therapeutic use , Ergocalciferols/blood , Ergocalciferols/therapeutic use , Follow-Up Studies , Humans , Male , Parathyroid Neoplasms/blood , Parathyroid Neoplasms/surgery , Radiography , Rickets/blood , Rickets/diagnostic imaging , Rickets/drug therapy , Time Factors , Vitamin D Deficiency/blood , Vitamin D Deficiency/diagnostic imaging , Vitamin D Deficiency/drug therapy
11.
FASEB J ; 21(4): 976-94, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17242160

ABSTRACT

All organisms, from simple invertebrates to complex human beings, exist in different colors and patterns, which arise from the unique distribution of pigments throughout the body. Pigmentation is highly heritable, being regulated by genetic, environmental, and endocrine factors that modulate the amount, type, and distribution of melanins in the skin, hair, and eyes. In addition to its roles in camouflage, heat regulation, and cosmetic variation, melanin protects against UV radiation and thus is an important defense system in human skin against harmful factors. Being the largest organ of the body that is always under the influence of internal and external factors, the skin often reacts to those agents by modifying the constitutive pigmentation pattern. The focus of this review is to provide an updated overview of important physiological and biological factors that increase pigmentation and the mechanisms by which they do so. We consider endocrine factors that induce temporary (e.g., during pregnancy) or permanent (e.g., during aging) changes in skin color, environmental factors (e.g., UV), certain drugs, and chemical compounds, etc. Understanding the mechanisms by which different factors and compounds induce melanogenesis is of great interest pharmaceutically (as therapy for pigmentary diseases) and cosmeceutically (e.g., to design tanning products with potential to reduce skin cancer risk).


Subject(s)
Melanocytes/cytology , Pigmentation , Skin Physiological Phenomena , Skin/metabolism , Cell Differentiation , Dermis/physiology , Endocrine System , Humans , Keratinocytes/cytology , Melanins/metabolism , Models, Biological , Stress, Physiological , Ultraviolet Rays
12.
J Pediatr ; 150(5): 527-30, 2007 May.
Article in English | MEDLINE | ID: mdl-17452230

ABSTRACT

OBJECTIVE: To determine whether increased thyroid hormones levels have an effect on various bone components (cortical vs cancellous bone). STUDY DESIGN: The anthropometric and 3-dimensional quantitative computed tomography (CT) bone measurements, including bone density (BD), cross-sectional area (CSA) of the lumbar spine and femur, and cortical bone area (CBA) of the femur, of 18 children and adolescents with untreated hyperthyroidism were reviewed and compared with those of age-, sex-, and ethnicity-matched historical controls. RESULTS: No significant differences in height, weight, body mass index (BMI), or pubertal staging between patients and controls were found. Cortical BD was significantly lower (P < .001) in children and adolescents with hyperthyroidism compared with historical controls. After adjusting for weight and height, no difference in femur CSA between hyperthyroid children and historical controls was evident. No significant correlations among thyroid hormone levels, antithyroid antibody levels, and cortical BD values were found. CONCLUSIONS: As determined by CT, cortical bone is the preferential site of bone loss in children and adolescents with untreated hyperthyroidism.


Subject(s)
Bone Density , Bone and Bones/anatomy & histology , Bone and Bones/diagnostic imaging , Hyperthyroidism/physiopathology , Tomography, X-Ray Computed , Adolescent , Child , Female , Humans , Male
13.
FASEB J ; 20(11): 1927-9, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16877522

ABSTRACT

Melanin synthesized by epidermal melanocytes protects the skin against UVR-induced DNA damage and skin cancer. Exposure to UVR increases the synthesis of the photoprotective eumelanin on activation of MC1R, a melanoma susceptibility gene. We studied the expression of MC1R under UVR and alpha-MSH stimulation in skin of different ethnic origins and in melanocytes of various pigmentary levels. This study identifies and characterizes a novel MC1R isoform (MC1R350) generated by alternative splicing of the classically known MC1R (MC1R317). We demonstrate that the melanin content of melanocytes shows a significant positive correlation with MC1R317 levels but correlates inversely with the amount of MC1R350, suggesting that this latter isoform could act as a negative regulator of melanin synthesis. We confirmed that hypothesis by showing that while MC1R317 signaling significantly increases the expression of MITF and tyrosinase, two key factors in the melanin synthesis pathway, MC1R350 dramatically hampers their expression. In the skin, we show that UVR does not increase MC1R350 expression but does significantly increase MC1R317. Taken together, our results strongly suggest that MC1R350 acts as a negative regulator of skin pigmentation and demonstrate for the first time that MC1R isoform-specific expression is closely related to skin pigmentation and photoprotection.


Subject(s)
Receptor, Melanocortin, Type 1/physiology , Skin Pigmentation/radiation effects , Skin/radiation effects , Ultraviolet Rays , Alternative Splicing/radiation effects , Cell Division , Cells, Cultured , Humans , Infant, Newborn , Male , Melanins/physiology , Melanins/radiation effects , Protein Isoforms/drug effects , Protein Isoforms/physiology , Receptor, Melanocortin, Type 1/genetics , Receptor, Melanocortin, Type 1/radiation effects , Skin Pigmentation/physiology , alpha-MSH/metabolism
14.
Biochem J ; 394(Pt 1): 43-50, 2006 Feb 15.
Article in English | MEDLINE | ID: mdl-16232122

ABSTRACT

Proteasomes are multicatalytic proteinase complexes within cells that selectively degrade ubiquitinated proteins. We have recently demonstrated that fatty acids, major components of cell membranes, are able to regulate the proteasomal degradation of tyrosinase, a critical enzyme required for melanin biosynthesis, in contrasting manners by relative increases or decreases in the ubiquitinated tyrosinase. In the present study, we show that altering the intracellular composition of fatty acids affects the post-Golgi degradation of tyrosinase. Incubation with linoleic acid (C18:2) dramatically changed the fatty acid composition of cultured B16 melanoma cells, i.e. the remarkable increase in polyunsaturated fatty acids such as linoleic acid and arachidonic acid (C20:4) was compensated by the decrease in monounsaturated fatty acids such as oleic acid (C18:1) and palmitoleic acid (C16:1), with little effect on the proportion of saturated to unsaturated fatty acid. When the composition of intracellular fatty acids was altered, tyrosinase was rapidly processed to the Golgi apparatus from the ER (endoplasmic reticulum) and the degradation of tyrosinase was increased after its maturation in the Golgi. Retention of tyrosinase in the ER was observed when cells were treated with linoleic acid in the presence of proteasome inhibitors, explaining why melanin synthesis was decreased in cells treated with linoleic acid and a proteasome inhibitor despite the abrogation of tyrosinase degradation. These results suggest that the intracellular composition of fatty acid affects the processing and function of tyrosinase in connection with the ubiquitin-proteasome pathway and suggest that this might be a common physiological approach to regulate protein degradation.


Subject(s)
Linoleic Acid/metabolism , Monophenol Monooxygenase/metabolism , Palmitic Acid/metabolism , Proteasome Endopeptidase Complex/metabolism , Ubiquitin/metabolism , Animals , Cell Line , Endoplasmic Reticulum/metabolism , Golgi Apparatus/metabolism , Leupeptins , Mice , Protein Transport
15.
Biochem J ; 391(Pt 2): 249-59, 2005 Oct 15.
Article in English | MEDLINE | ID: mdl-15960609

ABSTRACT

Dopachrome tautomerase (Dct) is a type I membrane protein and an important regulatory enzyme that plays a pivotal role in the biosynthesis of melanin and in the rapid metabolism of its toxic intermediates. Dct-mutant melanocytes carrying the slaty or slaty light mutations were derived from the skin of newborn congenic C57BL/6J non-agouti black mice and were used to study the effect(s) of these mutations on the intracellular trafficking of Dct and on the pigmentation of the cells. Dct activity is 3-fold lower in slaty cells compared with non-agouti black melanocytes, whereas slaty light melanocytes have a surprisingly 28-fold lower Dct activity. Homology modelling of the active site of Dct suggests that the slaty mutation [R194Q (Arg194-->Gln)] is located in the active site and may alter the ability of the enzyme to transform the substrate. Transmembrane prediction methods indicate that the slaty light mutation [G486R (Gly486-->Arg)] may result in the sliding of the transmembrane domain towards the N-terminus, thus interfering with Dct function. Chemical analysis showed that both Dct mutations increase pheomelanin and reduce eumelanin produced by melanocytes in culture. Thus the enzymatic activity of Dct may play a role in determining whether the eumelanin or pheomelanin pathway is preferred for pigment biosynthesis.


Subject(s)
Intramolecular Oxidoreductases/genetics , Intramolecular Oxidoreductases/metabolism , Melanins/biosynthesis , Melanocytes/metabolism , Amino Acid Sequence , Animals , Binding Sites , Cells, Cultured , Gene Expression Regulation, Enzymologic , Melanocytes/cytology , Mice , Molecular Sequence Data , Protein Conformation , Protein Transport , Sequence Homology, Amino Acid
16.
IUBMB Life ; 62(9): 703-5, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20836129
17.
FASEB J ; 17(14): 2154-6, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14500544

ABSTRACT

Five melanocortin receptors, which form a subfamily of G protein-coupled receptors, are expressed in mammalian tissues and regulate such diverse physiological processes as pigmentation, adrenal function, energy homeostasis, feeding efficiency, and sebaceous gland lipid production, as well as immune and sexual function. Pigmentation in mammals is stimulated by alpha-melanocyte stimulating hormone (MSH), which binds to the melanocortin 1 receptor (Mc1r) and induces an activation of melanogenic enzymes through stimulation of adenylate cyclase and protein kinase A. The antagonist agouti signal protein (ASP) interacts with the Mc1r and blocks its stimulation by MSH. We examined the influence of ASP or MSH on Mc1r gene expression, and we report that both ligands influence the Mc1r 5' promoter structure in distinct manners. Our study further shows that MSH regulates Mc1r function at both the mRNA and protein levels, whereas ASP acts only on its translation.


Subject(s)
Receptors, Melanocortin/genetics , Agouti Signaling Protein , Animals , Cells, Cultured , Gene Expression Regulation , Intercellular Signaling Peptides and Proteins/pharmacology , Melanocytes/drug effects , Melanocytes/metabolism , Mice , Models, Biological , Promoter Regions, Genetic , Protein Biosynthesis , RNA, Messenger/chemistry , RNA, Messenger/metabolism , Receptors, Melanocortin/agonists , Receptors, Melanocortin/metabolism , Transcription, Genetic/drug effects , alpha-MSH/pharmacology
18.
J Pediatr Endocrinol Metab ; 17(6): 889-93, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15270407

ABSTRACT

Low bone density (BD) has been reported in patients with hyperthyroidism. Whether or not levothyroxine (LT4) therapy in children with congenital hypothyroidism (CH) affects BD is unclear. Medical records of 45 patients with various etiologies of CH who had at least one BD measurement (32 female, mean age 7.6 +/- 2.6 years) were reviewed. The mean LT4 dose was 3.6 +/- 0.88 microg/kg/day. Cancellous bone density (CaBD) was measured by quantitative computed tomography (CT) in all 45 patients and 20 had measurements of cortical bone density (CoBD), cross-sectional area (CSA) and cortical bone area (CBA) of the femur. TSH levels were considered partially or completely suppressed when values were <1.0 or <0.5 microIU/ml, respectively. The control group consisted of age- and gender-matched healthy children. No significant differences were found in CaBD, CoBD, CSA, or CBA between patients with CH and controls. There were no significant differences between initial and subsequent BD measurements. No correlations were found between CaBD and etiology of CH, dose or duration of LT4 therapy, or serum TSH. In pre-pubertal children with CH, LT4 appears to have no significant effect on BD. Moreover, absence or hypoplasia of the thyroid parenchyma appears to have no significant impact on bone formation within the first 10 years of life.


Subject(s)
Bone Density/drug effects , Hyperthyroidism/diagnostic imaging , Hyperthyroidism/metabolism , Thyroxine/adverse effects , Tomography, X-Ray Computed , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Hyperthyroidism/congenital , Hyperthyroidism/drug therapy , Male , Retrospective Studies , Thyroxine/administration & dosage , Thyroxine/therapeutic use
19.
J Dermatol Sci ; 72(2): 168-76, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23867358

ABSTRACT

BACKGROUND: The effects of retinoids on melanogenesis and their mechanism as depigmenting agents in topical therapy have not been fully elucidated. Conflicting data about their impact on melanogenic pathways have been reported. OBJECTIVE: To investigate the effects of all-trans-retinoic acid (ATRA) on normal human melanocytes from Caucasian subjects. METHODS: We assessed ATRA's cytotoxicity by measuring viability with a cell proliferation assay, and apoptotic effects using Annexin V and γ-H2AX markers. ATRA's melanogenic activity was investigated based on spectrophotometric measurement of melanin content and tyrosinase enzymatic activity. Tyrosinase expression was assessed by Western blotting. We tested the antioxidant activity of superoxide dismutase (SOD) and catalase (CAT) in melanocytes using a spectrophotometric assay. RESULTS: Of the concentrations tested in this 72h time-course study, the 1.0µM ATRA had a well-defined two-stage pro-melanogenic and pro-apoptotic effect on melanocytes. In the first 6h, treated cells showed significant increase (p≤0.01) of melanin content, tyrosinase, SOD, and CAT activities compared to the controls. While overall tyrosinase expression was not affected by ATRA, all other tested parameters decreased progressively beyond the short-term point of 6h. ATRA treatment of over 6h induced melanocyte apoptosis, as shown by the time-dependent decrease in cell viability, coupled with significant increase in Annexin V positive cells and nuclear accumulation of γ-H2AX foci. CONCLUSION: The results obtained using this testing platform show a biphasic ATRA action: immediate pro-melanogenic effect and longer-term exposure pro-apoptotic activity. These data qualify ATRA as a potent tool to better understand the mechanisms that regulate the pigmentary system.


Subject(s)
Apoptosis , Melanocytes/drug effects , Tretinoin/pharmacology , Administration, Topical , Adult , Annexin A5/metabolism , Antioxidants/metabolism , Catalase/metabolism , Cell Proliferation , Cell Survival , Cells, Cultured , Histones/metabolism , Humans , Melanins/metabolism , Melanocytes/cytology , Melanocytes/metabolism , Microscopy, Phase-Contrast , Monophenol Monooxygenase/metabolism , Phenotype , Spectrophotometry , Superoxide Dismutase/metabolism , Time Factors , Young Adult
20.
Endocrinol Metab Clin North Am ; 41(4): 713-34, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23099266

ABSTRACT

Turner syndrome (TS) and Noonan syndrome (NS) have short stature as a constant feature; however, both conditions can present clinicians with a challenging array of genetic, cardiovascular, developmental, and psychosocial issues. In recent years, important advances have been achieved in each of these areas. This article reviews these two syndromes and provides updates on recent developments in diagnostic evaluation, growth and development, psychological issues, and treatment options for patients with TS and NS.


Subject(s)
Noonan Syndrome , Turner Syndrome , Female , Growth Disorders/drug therapy , Growth Disorders/etiology , Growth Hormone/therapeutic use , Humans , Male , Noonan Syndrome/complications , Noonan Syndrome/diagnosis , Noonan Syndrome/physiopathology , Noonan Syndrome/therapy , Primary Ovarian Insufficiency/drug therapy , Primary Ovarian Insufficiency/etiology , Recombinant Proteins/therapeutic use , Turner Syndrome/complications , Turner Syndrome/diagnosis , Turner Syndrome/physiopathology , Turner Syndrome/therapy
SELECTION OF CITATIONS
SEARCH DETAIL